Stem Cell Therapies for Cardiovascular and Metabolic Disorders Markets, 2012-2018 & 2019-2030 - ResearchAndMarkets.com

The "Stem
Cell Therapies for Cardiovascular and Metabolic Disorders, 2019-2030"
report has been added to ResearchAndMarkets.com's
offering.

The Stem Cell Therapies for Cardiovascular & Metabolic Disorders,
2019-2030 report features an extensive study of the current market
landscape and the future potential of stem cell therapies in treating
the aforementioned clinical conditions.

The study includes all stem cell therapies that are being developed for
the treatment of cardiovascular and metabolic disorders. In addition, we
have provided a list of stem cell therapies being developed for stroke,
a condition associated with vasculature in the brain.

Amongst other elements, the report features the following:

• A detailed assessment of the current market landscape of stem cell
  therapies with respect to target therapeutic area (cardiovascular and
  metabolic), phase of development (approved, phase III, phase II, phase
  I and preclinical / discovery), target disease indications
  (Cardiovascular: heart failure, myocardial infarction, critical limb
  ischemia, angina, peripheral arterial / vascular diseases, myocardial
  ischemia, myocardial fibrosis, cardiomyopathy and coronary
  microvascular dysfunction; Metabolic: diabetes, mucopolysaccharidosis
  type III, ADA-SCID, obesity, mitochondrial disorders and metachromatic
  leukodystrophy), source of cells (autologous and allogenic), type of
  stem cells (adult multipotent, adult pluripotent, embryonic
  multipotent, embryonic pluripotent and others), stem cell lineage
  (bone marrow, peripheral blood, adipose tissue, cardiosphere, muscle,
  Wharton's jelly, umbilical cord, placenta, dental pulp, cord blood and
  pancreas), and route of administration (intramyocardial,
  intramuscular, intravenous, intracoronary, subcutaneous implantation
  and surgical implantation).
• An analysis highlighting the key unmet needs across cardiovascular and
  metabolic disorders, featuring insights generated from social media
  posts, recent scientific publications, patient blogs and the views of
  contemporary key opinion leaders as expressed on online platforms.
• An overview of the focus areas of therapy developers, including an
  assessment of the existing opportunity for stem cell therapies across
  diverse therapeutic indications.
• An insightful company competitiveness analysis featuring a
  three-dimensional bubble representation, highlighting the key players
  in this domain on the basis of the strength of their respective
  product portfolios, taking into consideration the number of therapies
  under development, phase of development of these therapies, number of
  disease indications being targeted and geographical distribution of
  affiliated clinical trials.
• An analysis of the partnerships that have been established in the
  domain in the period 2012-2018, covering R&D collaborations, licensing
  agreements, mergers and acquisitions, product development and/or
  commercialization agreements, manufacturing agreements, clinical trial
  agreements, process development agreements, and other relevant deals.
• An analysis of the investments made at various stages of development
  in companies that are focused in this area, including seed financing,
  venture capital financing, capital raised from IPOs / secondary
  offerings, debt financing and grants.
• An analysis of contemporary peer-reviewed scientific research articles
  published during the period 2013-2018, highlighting the key focus
  areas of the ongoing research activity, in terms of therapeutic area,
  target disease indication, and source of cells.
• Comprehensive profiles of approved and late-stage clinical products;
  each profile features an overview of the therapy, its mechanism of
  action, history of development, current development status, key
  clinical trial results, details on recommended dose, price and
  manufacturing process (wherever available).
• One of the key objectives of the report was to understand the primary
  growth drivers and estimate the future size of the market. Based on
  parameters, such as target consumer segments, likely adoption rates
  and expected pricing, we have provided an informed estimate of the
  likely evolution of the market in the short to mid-term and long term,
  for the period 2019-2030.
  
• The report includes information on (potential) sales-based revenues
  generated by stem cell therapies that are currently marketed or are in
  late stages of development for the treatment of cardiovascular and
  metabolic disorders. Additionally, it presents details on the likely
  distribution of the current and forecasted opportunity across [A]
  target therapeutic areas (cardiovascular and metabolic), [B] target
  disease indications (myocardial ischemia, heart failure, critical limb
  ischemia, diabetes, ADA-SCID, metachromatic leukodystrophy, and other
  cardiovascular and metabolic disorders ), [C] type of stem cells
  (adult multipotent, adult pluripotent and embryonic multipotent), [D]
  source of cells (autologous and allogenic), [E] stem cell lineage
  (bone marrow, peripheral blood and others), [F] route of
  administration (intramyocardial, intracoronary, intramuscular,
  intravenous and surgical implantation) and [G] key geographical
  regions (North America, Europe and Asia Pacific). To account for the
  uncertainties associated with the development of novel therapy
  products and to add robustness to our model, we have provided three
  forecast scenarios, portraying the conservative, base and optimistic
  tracks of the market's evolution.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Unmet Need Analysis

6. Key Therapeutic Areas

7. Company Competitiveness Analysis

8. Partnerships And Collaborations

9. Funding And Investment Analysis

10. Publication Analysis

11. Stem Cell Therapies For Cardiovascular Disorders: Therapy Profiles

12. Stem Cell Therapies For Metabolic Disorders: Therapy Profiles

13. Market Forecast

14. Conclusion

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List Of Companies And Organizations

For more information about this report visit https://www.researchandmarkets.com/r/9oaflt

View source version on businesswire.com: https://www.businesswire.com/news/home/20190426005328/en/